Pelabresib Plus Ruxolitinib Improves Signs of Underlying Myelofibrosis Pathobiology and Provides Clinical Benefit Over JAK Inhibitor Monotherapy By Ogkologos - March 25, 2025 779 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MANIFEST-2 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer MOST POPULAR How TRACERx is helping us predict lung cancer’s next move April 12, 2023 Quitting Smoking Improves Survival in People with Lung Cancer September 14, 2021 EMA Recommends Extension of Indications for Avelumab December 17, 2020 Co-Existing with COVID-19: Should I go back to work? Do I... June 19, 2020 Load more HOT NEWS Stage IV Cancer Patient Clinging to Life Overseas While Family Raises... Blood Test for Early Detection of Cancer: Final Study Results Support... Five Questions With…Desiree. Nivolumab Does Not Prolong Overall Survival Compared with Sorafenib In First-Line...
